Alercell, Inc

Alercell, Inc

Alercell, Inc. is a molecular diagnostics company pioneering novel therapeutics to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in Oncology in-vitro Diagnostic Testing and Neuroscience. Alercell is a true innovator, disruptor, and leader in the field of preventative oncolog ...
Products

Recently updated

Lung Cancer Molecular Diagnostic Test
LENA S1

LENA S1 is first methylation-based molecular diagnostic test for lung cancer. It enables early diagnosis of lung cancer and very accurate localization of the disease, if present.
More details

Leukemia Diagnostic Test
LENA Q51

LENA Q51 is the first leukemia diagnostic test that is able to test up to 51 genes mutations and uses an innovative approach to target the gene mutations, the clonogenic gene rearrangements and abnormal gene expression. The test can be administered in a qPCR machine and delivers results within less than three hours as compared to an average of 3 to 6 weeks taken by the current detection system.
More details

Molecular Diagnostic (DX) Platform
Lena Leukemia Platform

LENA Molecular Diagnostic (DX) Platform has been created to offer practitioners access to the largest variety of leukemia-related diagnostic tests for early detection and guidance in treatments. All LENA tests are new generation DNA sequencing tests that offer high quality testing with the highest accuracy and sensitivity available on the market.
More details

Clinical Laboratory

Lung Cancer Molecular Diagnostic Test
LENA S1

LENA S1 is first methylation-based molecular diagnostic test for lung cancer. It enables early diagnosis of lung cancer and very accurate localization of the disease, if present.
More details

Leukemia Diagnostic Test
LENA Q51

LENA Q51 is the first leukemia diagnostic test that is able to test up to 51 genes mutations and uses an innovative approach to target the gene mutations, the clonogenic gene rearrangements and abnormal gene expression. The test can be administered in a qPCR machine and delivers results within less than three hours as compared to an average of 3 to 6 weeks taken by the current detection system.
More details

Molecular Diagnostic (DX) Platform
Lena Leukemia Platform

LENA Molecular Diagnostic (DX) Platform has been created to offer practitioners access to the largest variety of leukemia-related diagnostic tests for early detection and guidance in treatments. All LENA tests are new generation DNA sequencing tests that offer high quality testing with the highest accuracy and sensitivity available on the market.
More details
Copyright © 2000-2026 TradeMed.com. All rights reserved. | Terms And Conditions